Discovery video about our commitment to vaccine research

Our Mission

- To conduct the highest quality basic and translational research on vaccines and human responses to infection

- To train promising young scientists at all levels in contemporary approaches to vaccine and immunology research.

+ Learn More

Recent News

  • Dr. Crowe to present cutting-edge research at Discovery Lecture
    Dr. Crowe will present his lecture, "Next Generation Vaccines" on Thursday, May 22, at 4 pm in 208 Light Hall as a part of Vanderbilt's Discovery Lecture series. This series seeks to respond to the requests of the Biomedical Advisory Board in presenting discussion-stimulating topics in research. Dr. Borden Lacy and Dr. Simon Mallal will also present findings that showcase Vanderbilt University's position on the cutting-edge of medical research; their lectures are respectively entitled "Structure and Function of Clostridium difficile Toxins A and B" and "Personalized Immunology." Learn more about the Discovery Lecture series.
  • Dr. Crowe Elected to the Institute of Medicine

    This week, the National Academies announced the election of the Vanderbilt Vaccine Center's own Dr. Crowe to the Institute of Medicine (IOM). The now over 1900 members of the IOM serve as an advising council to the United States on health policy, practice, and research. Dr. Nancy Brown, chair and physician-in-chief of the Vanderbilt Medical Center, was inducted into the IOM alongside Dr. Crowe, bringing the total number of current Vanderbilt faculty who are members of the IOM to 29. 


    "It is with great enthusiasm that we welcome our esteemed colleagues to the Institute of Medicine," said IOM President Victor J. Dzau.  "These leaders' tremendous achievements have contributed significantly to advancing health and medicine.  The expertise and knowledge they bring to the IOM will encourage and enhance its success."


    Dr. Jeff Balser, dean of the Vanderbilt University School of Medicine, congratulated Doctors Brown and Crowe on their achievement, stating, "Both are exemplary physician scientists who have already made profoundly important contributions to their respective fields and will no doubt continue along this trajectory."


    Currently, Dr. Crowe's research focuses on understanding and developing vaccines for adult and childhood infectious and viral diseases. He responded to his election, stating, “I am humbled to be included (in the IOM), and excited that the work of so many researchers at Vanderbilt in the field of vaccine and immunology research is recognized is this way. [Vanderbilt] is one of the very top venues for impacting national and international vaccine policy.”


    Congratulations to Dr. Crowe for all of his great efforts and achievements!



    Dr. Crowe is currently developing immunotherapies against Ebola virus, among other diseases. For more information on Dr. Crowe and his work, visit his biography page



    Please send requests for more information or inquiries to

  • Senator Alexander Meets with Crowe Lab to Learn About the Fight Against Ebola
    On Wednesday, Senator Lamar Alexander visited Vanderbilt University Medical Center to meet with Dr. Crowe and his team in order to learn about the existing defenses against Ebola. Dr. Crowe and his lab conduct research which aims to develop a drug to protect individuals against the Ebola virus that has recently spread through West Africa. Senator Alexander declared last Tuesday that the growing threat of the Ebola virus must be taken "as seriously as we take the threat of ISIS" and, in a more recent committee hearing, called Ebola "one of the most explosive, dangerous, deadly epidemics in modern times." In March of this year, a collaborative research group comprised of Dr. James Crowe, Dr. Thomas Geisbert and Dr. Alexander Bukreyev of UTMB, Dr. John Eldrige of Profectus Biosciences in Baltimore, and Dr. Ian MacLachlan of Tekmira Pharmaceuticals in Canada was awarded a grant to develop methods of treatment and prevention of Ebola and Marburg virus infections. The federally-funded project will provide $26 million over the next five years to develop and test broad-spectrum treatments and vaccines for Ebola and Marburg viruses. Dr. Crowe explains, "The research tools we are using, human monoclonal antibodies derived from the blood cells of naturally infected human survivors, also can be developed as prevention and treatment biologic medicines (for use) in the field.” While the Vanderbilt Vaccine Center has been studying Ebola and developing prevention and treatment methods for several years, the new funding for Ebola research development comes not a minute too soon. Earlier today in Washington, President Obama spoke to a summit of world leaders, stated that Ebola is a "growing threat to regional and global security” and called for immediate, universal effort to stop the spread of the virus and fund research for development of a treatment. Photo: Anne Rayner, VU